Do analysts prefer TVRD or CPIX?

Tvardi Therapeutics currently has a consensus price target of $18.00, indicating a potential upside of 862.57%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tvardi Therapeutics is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tvardi Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78 Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TVRD or PLYX more profitable?

Polaryx Therapeutics' return on equity of 0.00% beat Tvardi Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tvardi Therapeutics N/A -145.40% -91.11% Polaryx Therapeutics N/A N/A N/A

Does the media prefer TVRD or PLYX?

In the previous week, Polaryx Therapeutics had 1 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 5 mentions for Polaryx Therapeutics and 4 mentions for Tvardi Therapeutics. Tvardi Therapeutics' average media sentiment score of 0.97 beat Polaryx Therapeutics' score of 0.70 indicating that Tvardi Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tvardi Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Polaryx Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is TVRD or CGTX more profitable?

Cognition Therapeutics' return on equity of -50.17% beat Tvardi Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tvardi Therapeutics N/A -145.40% -91.11% Cognition Therapeutics N/A -50.17% -40.22%

Does the media refer more to TVRD or CGTX?

In the previous week, Tvardi Therapeutics and Tvardi Therapeutics both had 4 articles in the media. Cognition Therapeutics' average media sentiment score of 1.40 beat Tvardi Therapeutics' score of 0.97 indicating that Cognition Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tvardi Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cognition Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VRCA or TVRD?

In the previous week, Tvardi Therapeutics had 1 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 4 mentions for Tvardi Therapeutics and 3 mentions for Verrica Pharmaceuticals. Tvardi Therapeutics' average media sentiment score of 0.97 beat Verrica Pharmaceuticals' score of 0.62 indicating that Tvardi Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Verrica Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tvardi Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor FBIO or TVRD?

In the previous week, Tvardi Therapeutics had 1 more articles in the media than Fortress Biotech. MarketBeat recorded 4 mentions for Tvardi Therapeutics and 3 mentions for Fortress Biotech. Tvardi Therapeutics' average media sentiment score of 0.97 beat Fortress Biotech's score of 0.47 indicating that Tvardi Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortress Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tvardi Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Tvardi Therapeutics (TVRD) Competitors

$1.87 +0.04 (+1.91%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$1.86 -0.02 (-0.80%)

As of 09/11/2026 07:57 PM Eastern

Compare

TVRD vs. CPIX, PLYX, CGTX, VRCA, and FBIO

Should you buy Tvardi Therapeutics stock or one of its competitors? Tvardi Therapeutics's main competitors and comparable companies include Cumberland Pharmaceuticals (CPIX), Polaryx Therapeutics (PLYX), Cognition Therapeutics (CGTX), Verrica Pharmaceuticals (VRCA), and Fortress Biotech (FBIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Tvardi Therapeutics compare to Cumberland Pharmaceuticals?

Tvardi Therapeutics (NASDAQ:TVRD) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation.

In the previous week, Tvardi Therapeutics had 3 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 4 mentions for Tvardi Therapeutics and 1 mentions for Cumberland Pharmaceuticals. Cumberland Pharmaceuticals' average media sentiment score of 1.87 beat Tvardi Therapeutics' score of 0.97 indicating that Cumberland Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Tvardi Therapeutics	Positive
Cumberland Pharmaceuticals	Very Positive

Tvardi Therapeutics has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market. Comparatively, Cumberland Pharmaceuticals has a beta of 0.13, indicating that its share price is 87% less volatile than the broader market.

Tvardi Therapeutics has a net margin of 0.00% compared to Cumberland Pharmaceuticals' net margin of -34.40%. Cumberland Pharmaceuticals' return on equity of -28.81% beat Tvardi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tvardi Therapeutics	N/A	-145.40%	-91.11%
Cumberland Pharmaceuticals	-34.40%	-28.81%	-9.25%

Cumberland Pharmaceuticals has higher revenue and earnings than Tvardi Therapeutics. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tvardi Therapeutics	$7.14M	3.49	-$18.21M	-$2.79	N/A
Cumberland Pharmaceuticals	$44.52M	2.15	-$2.84M	-$0.71	N/A

44.7% of Tvardi Therapeutics shares are held by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. 7.4% of Tvardi Therapeutics shares are held by insiders. Comparatively, 42.1% of Cumberland Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Tvardi Therapeutics currently has a consensus price target of $18.00, indicating a potential upside of 862.57%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tvardi Therapeutics is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Tvardi Therapeutics beats Cumberland Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Tvardi Therapeutics compare to Polaryx Therapeutics?

Tvardi Therapeutics (NASDAQ:TVRD) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

44.7% of Tvardi Therapeutics shares are held by institutional investors. 7.4% of Tvardi Therapeutics shares are held by insiders. Comparatively, 45.8% of Polaryx Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Tvardi Therapeutics currently has a consensus price target of $18.00, indicating a potential upside of 862.57%. Polaryx Therapeutics has a consensus price target of $7.67, indicating a potential upside of 281.43%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Tvardi Therapeutics is more favorable than Polaryx Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Polaryx Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Polaryx Therapeutics has lower revenue, but higher earnings than Tvardi Therapeutics. Polaryx Therapeutics is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tvardi Therapeutics	$7.14M	3.49	-$18.21M	-$2.79	N/A
Polaryx Therapeutics	N/A	N/A	-$8.98M	-$0.08	N/A

Polaryx Therapeutics' return on equity of 0.00% beat Tvardi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tvardi Therapeutics	N/A	-145.40%	-91.11%
Polaryx Therapeutics	N/A	N/A	N/A

In the previous week, Polaryx Therapeutics had 1 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 5 mentions for Polaryx Therapeutics and 4 mentions for Tvardi Therapeutics. Tvardi Therapeutics' average media sentiment score of 0.97 beat Polaryx Therapeutics' score of 0.70 indicating that Tvardi Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tvardi Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Polaryx Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Tvardi Therapeutics beats Polaryx Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Tvardi Therapeutics compare to Cognition Therapeutics?

Tvardi Therapeutics (NASDAQ:TVRD) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

Cognition Therapeutics' return on equity of -50.17% beat Tvardi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tvardi Therapeutics	N/A	-145.40%	-91.11%
Cognition Therapeutics	N/A	-50.17%	-40.22%

In the previous week, Tvardi Therapeutics and Tvardi Therapeutics both had 4 articles in the media. Cognition Therapeutics' average media sentiment score of 1.40 beat Tvardi Therapeutics' score of 0.97 indicating that Cognition Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tvardi Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cognition Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tvardi Therapeutics has higher revenue and earnings than Cognition Therapeutics. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tvardi Therapeutics	$7.14M	3.49	-$18.21M	-$2.79	N/A
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.17	N/A

44.7% of Tvardi Therapeutics shares are owned by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are owned by institutional investors. 7.4% of Tvardi Therapeutics shares are owned by company insiders. Comparatively, 11.1% of Cognition Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Tvardi Therapeutics has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market.

Tvardi Therapeutics presently has a consensus target price of $18.00, suggesting a potential upside of 862.57%. Cognition Therapeutics has a consensus target price of $3.33, suggesting a potential upside of 239.17%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Tvardi Therapeutics is more favorable than Cognition Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Tvardi Therapeutics beats Cognition Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Tvardi Therapeutics compare to Verrica Pharmaceuticals?

Verrica Pharmaceuticals (NASDAQ:VRCA) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

In the previous week, Tvardi Therapeutics had 1 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 4 mentions for Tvardi Therapeutics and 3 mentions for Verrica Pharmaceuticals. Tvardi Therapeutics' average media sentiment score of 0.97 beat Verrica Pharmaceuticals' score of 0.62 indicating that Tvardi Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Verrica Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tvardi Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are held by institutional investors. 52.9% of Verrica Pharmaceuticals shares are held by insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Tvardi Therapeutics has a net margin of 0.00% compared to Verrica Pharmaceuticals' net margin of -102.84%. Tvardi Therapeutics' return on equity of -145.40% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verrica Pharmaceuticals	-102.84%	-407.11%	-70.17%
Tvardi Therapeutics	N/A	-145.40%	-91.11%

Verrica Pharmaceuticals has higher revenue and earnings than Tvardi Therapeutics. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verrica Pharmaceuticals	$35.58M	2.37	-$17.89M	-$1.67	N/A
Tvardi Therapeutics	$7.14M	3.49	-$18.21M	-$2.79	N/A

Verrica Pharmaceuticals currently has a consensus target price of $12.67, indicating a potential upside of 157.98%. Tvardi Therapeutics has a consensus target price of $18.00, indicating a potential upside of 862.57%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tvardi Therapeutics is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Verrica Pharmaceuticals has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market. Comparatively, Tvardi Therapeutics has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market.

Summary

Tvardi Therapeutics beats Verrica Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Tvardi Therapeutics compare to Fortress Biotech?

Fortress Biotech (NASDAQ:FBIO) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

96.5% of Fortress Biotech shares are held by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are held by institutional investors. 28.5% of Fortress Biotech shares are held by insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Fortress Biotech has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market. Comparatively, Tvardi Therapeutics has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market.

Fortress Biotech currently has a consensus price target of $17.00, indicating a potential upside of 574.60%. Tvardi Therapeutics has a consensus price target of $18.00, indicating a potential upside of 862.57%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tvardi Therapeutics is more favorable than Fortress Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Tvardi Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

In the previous week, Tvardi Therapeutics had 1 more articles in the media than Fortress Biotech. MarketBeat recorded 4 mentions for Tvardi Therapeutics and 3 mentions for Fortress Biotech. Tvardi Therapeutics' average media sentiment score of 0.97 beat Fortress Biotech's score of 0.47 indicating that Tvardi Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortress Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tvardi Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fortress Biotech has a net margin of 163.32% compared to Tvardi Therapeutics' net margin of 0.00%. Fortress Biotech's return on equity of 83.47% beat Tvardi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	163.32%	83.47%	42.98%
Tvardi Therapeutics	N/A	-145.40%	-91.11%

Fortress Biotech has higher revenue and earnings than Tvardi Therapeutics. Tvardi Therapeutics is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$68.47M	1.23	$6.82M	$2.64	0.95
Tvardi Therapeutics	$7.14M	3.49	-$18.21M	-$2.79	N/A

Summary

Fortress Biotech beats Tvardi Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Tvardi Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TVRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TVRD vs. The Competition

Export

Metric	Tvardi Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$24.94M	$12.41B	$7.16B	$12.85B
Dividend Yield	N/A	2.64%	2.57%	11.17%
P/E Ratio	-0.67	799.75	274.94	25.36
Price / Sales	3.49	966.93	686.57	116.78
Price / Cash	N/A	88.17	76.65	51.52
Price / Book	0.84	10.39	10.33	6.20
Net Income	-$18.21M	$2.85B	$3.50B	$358.50M
7 Day Performance	-2.09%	-3.61%	-3.32%	-2.35%
1 Month Performance	5.65%	0.72%	-0.53%	-3.23%
1 Year Performance	-94.48%	3.61%	23.51%	8.79%

Tvardi Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TVRD Tvardi Therapeutics	3.5211 of 5 stars	$1.87 +1.9%	$18.00 +862.6%	-94.5%	$24.94M	$7.14M	N/A	80	News Coverage Analyst Upgrade
CPIX Cumberland Pharmaceuticals	0.8916 of 5 stars	$6.79 flat	N/A	+85.8%	$101.71M	$44.52M	N/A	80
PLYX Polaryx Therapeutics	3.2347 of 5 stars	$2.00 flat	$7.67 +283.3%	N/A	$99.70M	N/A	N/A	11	News Coverage Analyst Upgrade
CGTX Cognition Therapeutics	2.4439 of 5 stars	$1.03 flat	$3.33 +223.6%	-54.7%	$97.94M	N/A	N/A	20	Positive News
VRCA Verrica Pharmaceuticals	4.4736 of 5 stars	$5.30 flat	$12.67 +139.0%	+3.4%	$91.05M	$35.58M	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TVRD) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tvardi Therapeutics (TVRD) Competitors

TVRD vs. CPIX, PLYX, CGTX, VRCA, and FBIO

How does Tvardi Therapeutics compare to Cumberland Pharmaceuticals?

Summary

How does Tvardi Therapeutics compare to Polaryx Therapeutics?

Summary

How does Tvardi Therapeutics compare to Cognition Therapeutics?

Summary

How does Tvardi Therapeutics compare to Verrica Pharmaceuticals?

Summary

How does Tvardi Therapeutics compare to Fortress Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVRD vs. The Competition

Tvardi Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tvardi Therapeutics (TVRD) Competitors

TVRD vs. CPIX, PLYX, CGTX, VRCA, and FBIO

How does Tvardi Therapeutics compare to Cumberland Pharmaceuticals?

Does the media refer more to TVRD or CPIX?

Which has more volatility & risk, TVRD or CPIX?

Is TVRD or CPIX more profitable?

Which has better earnings & valuation, TVRD or CPIX?

Do institutionals and insiders have more ownership in TVRD or CPIX?

Do analysts prefer TVRD or CPIX?

Summary

How does Tvardi Therapeutics compare to Polaryx Therapeutics?

Do institutionals and insiders have more ownership in TVRD or PLYX?

Do analysts recommend TVRD or PLYX?

Which has preferable earnings & valuation, TVRD or PLYX?

Is TVRD or PLYX more profitable?

Does the media prefer TVRD or PLYX?

Summary

How does Tvardi Therapeutics compare to Cognition Therapeutics?

Is TVRD or CGTX more profitable?

Does the media refer more to TVRD or CGTX?

Which has preferable valuation & earnings, TVRD or CGTX?

Do insiders & institutionals hold more shares of TVRD or CGTX?

Which has more risk and volatility, TVRD or CGTX?

Do analysts rate TVRD or CGTX?

Summary

How does Tvardi Therapeutics compare to Verrica Pharmaceuticals?

Does the media favor VRCA or TVRD?

Do insiders & institutionals have more ownership in VRCA or TVRD?

Is VRCA or TVRD more profitable?

Which has better valuation & earnings, VRCA or TVRD?

Do analysts recommend VRCA or TVRD?

Which has more risk and volatility, VRCA or TVRD?

Summary

How does Tvardi Therapeutics compare to Fortress Biotech?

Do institutionals & insiders have more ownership in FBIO or TVRD?

Which has more volatility & risk, FBIO or TVRD?

Do analysts rate FBIO or TVRD?

Does the media favor FBIO or TVRD?

Is FBIO or TVRD more profitable?

Which has better valuation and earnings, FBIO or TVRD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TVRD vs. The Competition

Tvardi Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools